Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:5280436
Structure:
Synonyms:
(6Z,9Z,12Z,15Z)-1,1,1-trifluorohenicosa-6,9,12,15-tetraen-2-one
1,1,1-Trifluoro-6Z,9Z,12Z,15Z-heneicosatetraen-2-one
1,1,1-Trifluoromethyl-6,9,12,15-heieicosatetraen-2-one
149301-79-1
6,9,12,15-Heneicosatetraen-2-one, 1,1,1-trifluoro-, (6Z,9Z,12Z,15Z)-
6,9,12,15-Heneicosatetraen-2-one, 1,1,1-trifluoro-, (all-Z)-
A231_SIGMA
AACOCF3
AC1NQX0Q
AIDS-171530
AIDS171530
Arach-CF3
Arachidonic acid trifluoromethyl ketone
Arachidonyl trifluoromethyl ketone
Arachidonyl trifluoromethylketone
Arachidonyltrifluoromethane
Arachidonyltrifluoromethyl Ketone
ATFMK
C01397
C081565
C21H31F3O
CHEBI:2341
CHEMBL281211
LS-173349
NCGC00162420-01
ZINC03813524

Target

show target details
Uniprot ID:CASP3_MOUSE
Synonyms:
Apopain
CASP-3
Caspase-3
CPP-32
Cysteine protease CPP32
LICE
SCA-1
SREBP cleavage activity 1
Yama protein
EC-Numbers:3.4.22.56
Organism:Mouse
Mus musculus
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

18831921
Involvement of cPLA2 inhibition in dexamethasone-induced thymocyte apoptosis.. B Cinque; D Fanini; L Di Marzio; P Palumbo; C La Torre; V Donato; E Velardi; S Bruscoli; C Riccardi; M G Cifone (2008) International journal of immunopathology and pharmacology display abstract
Various molecular mechanisms have been suggested to be involved in dexamethasone induced thymocyte apoptosis. In this study we show that pharmacological inhibition of cytoplasmic PLA2 in mouse thymocytes for 18 h with arachidonyl trifluoromethyl ketone (AACOCF3) (10 microM) and palmitoyl trifluoromethyl ketone (PACOCF3) (10 microM) induced a drastic increase of thymocyte apoptosis comparable to that observed following Dex (10(-7) M) treatment, while inhibition of secretory PLA2 with p-bromophenacyl bromide (pBPB) (20 microM) did not. AACOCF3-induced thymocyte apoptosis, similarly to Dex-induced thymocyte apoptosis, was eliminated by cell pre-treatment with the PI-PLCbeta inhibitor, U73122, but not by the PC-PLC inhibitor D609. These observations were corroborated by the ability of AACOCF3, like Dex, to induce a rapid and transient increase in DAG generation. In addition, AACOCF3-induced apoptosis involved the activation of the acidic sphingomyelinase (aSMase) but not of the neutral sphingomyelinase (nSMase), as evaluated by measurements of enzyme activity in cell extracts following thymocyte exposure to AACOCF3 and by the ability of monensin to inhibit AACOCF3-induced thymocyte apoptosis. In addition, the AACOCF3 apoptotic effect resulted in an early increase of ceramide levels. AACOCF3-induced thymocyte apoptosis involved the activation of caspase 3, and cell pre-treatment with a caspase 3 inhibitor prevented AACOCF3-induced apoptosis. These observations suggest that cPLA2 inhibition may have a role in Dex-induced thymocyte apoptosis and highlight the importance of cPLA2 activity in thymocyte survival.